You are here: Industry Insights > Kite

News List

Kite licences Teneobio’s multiple myeloma targeting antibodies pharmaceutical-technology
April 06, 2020
Gilead unit Kite has signed a licence and collaboration agreement with Teneobio for sole rights to antibodies intended for the treatment of multiple myeloma.
Kite’s Yescarta yields positive results in ZUMA-1 trial in refractory large B-cell lymphoma pharmaceutical-business-review
December 11, 2019
Kite, a Gilead Company announced new data from the ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma.
Kite to open new manufacturing plant for cell therapies pharmaceutical-technology
July 18, 2019
Gilead Sciences subsidiary Kite Therapeutics will build a new facility in Oceanside, California, US, to develop and manufacture viral vectors, a key material in cell therapies production.
Gilead Appoints CEO of Kite contractpharma
July 15, 2019
Shaw brings extensive experience providing commercial, financial, strategic, medical and operations leadership across the biopharma industry.
CAR-T player Cell Medica names Kite’s European chief as CEO fiercebiotech
August 02, 2018
Cell Medica has appointed Chris Nowers as its CEO. Nowers joins the company from Gilead’s Kite Pharma at a time when Cell Medica is seeking to push CAR and TCR candidates through clinical development and on to the market.
Kite first to submit CAR-T therapy in Europe pharmatimes
August 02, 2017
Kite Pharma has submitted the first CAR-T cell therapy in Europe, seeking permission to market its axicabtagene ciloleucel (axi-cel) to treat patients with three subtypes of aggressive non-Hodgkin lymphoma
New 3-year data supports Kite ‘cure’ hopes for CAR-T pharmaphorum
July 24, 2017
A handful of patients with aggressive leukaemia appeared to have been cured thanks to CAR-T therapy, with some living more than four years with complete remission (CR).

Previous page 1 2 Next page